Search results for "Rate ratio"

showing 10 items of 48 documents

High ankle injury rate in adolescent basketball: A 3-year prospective follow-up study.

2016

This prospective study investigated the incidence and pattern of acute time-loss injuries in young female and male basketball players. Eight basketball teams (n=201; mean age 14.85±1.5) participated in the follow-up study (2011-2014). The coaches recorded player participation in practices and games on a team diary. A study physician contacted the teams once a week to check new injuries and interviewed the injured players. In total, 158 injuries occurred. The overall rate of injury (per 1000 hours) was 2.64 (95% CI 2.23-3.05). Injury rate was 34.47 (95% CI 26.59-42.34) in basketball games and 1.51 (95% CI 1.19-1.82) in team practices. Incidence rate ratio (IRR) between game and practice was …

Malesports injurymedicine.medical_specialtyBasketballAdolescentPhysical Therapy Sports Therapy and RehabilitationBasketballKnee InjuriesRate ratio03 medical and health sciences0302 clinical medicineAnkle injuryEpidemiologyMedicineHumansOrthopedics and Sports MedicineAnkle InjuriesProspective StudiesProspective cohort studyFinland030222 orthopedicsbusiness.industryIncidence (epidemiology)IncidenceYouth SportsFollow up studiesta3141030229 sport sciencesrecurrent injurymedicine.anatomical_structurePhysical therapySprains and StrainsepidemiologyFemaleteam sportsAnklebusinesshuman activitiesFollow-Up StudiesScandinavian journal of medicinescience in sports
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct

Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials.

2018

Abstract Background An extensive clinical trial program supports the efficacy and safety of tiotropium/olodaterol in chronic obstructive pulmonary disease (COPD). We examined the safety of tiotropium/olodaterol compared with tiotropium in a large population of patients, focusing on cardiovascular and respiratory events. Methods Patients (n = 9942) who received once-daily tiotropium/olodaterol 5/5 μg or tiotropium 5 μg (via Respimat®) in TONADO 1 & 2 and DYNAGITO were included. The number of patients and exposure-adjusted rate of events are presented for adverse events (AEs), serious AEs (SAEs), AEs leading to discontinuation, and cardiovascular and respiratory events. Findings Fewer patient…

Pulmonary and Respiratory MedicineMaleRiskmedicine.medical_specialtyTime FactorsRate ratiolaw.invention03 medical and health scienceschemistry.chemical_compoundPulmonary Disease Chronic Obstructive0302 clinical medicineRandomized controlled triallawCentral Nervous System DiseasesRisk FactorsInternal medicinemedicineHumans030212 general & internal medicineTiotropium BromideAdverse effectRandomized Controlled Trials as TopicCOPDbusiness.industryIncidenceOlodaterolmedicine.diseasehumanitiesrespiratory tract diseasesDiscontinuationBenzoxazinesClinical trialDrug Combinations030228 respiratory systemchemistryCardiovascular DiseasesFemaleSafetybusinesshuman activitiesMaceRespiratory medicine
researchProduct

Alternative ways of expressing FEV1 and mortality in elderly people with and without COPD

2013

Expressing forced expiratory volume in 1 s (FEV1) as % predicted relies on the assumption of proportional variability and generalisability of prediction equations that may be unrealistic, especially for elderly people. We evaluated the prognostic implications of alternative ways of expressing FEV1. We enrolled 318 patients with chronic obstructive pulmonary disease (COPD) and 475 controls in the Salute Respiratoria nell'Anziano (SARA) study. The risk for 5-, 10- and 15-year mortality associated with FEV1 was studied by expressing FEV1 % pred, standardised by height cubed (FEV1 · Ht(-3)) and as a multiple of the sex-specific first percentile (FEV1 quotient (FEV1Q)). In the group with COPD, t…

Pulmonary and Respiratory MedicineSpirometryMalemedicine.medical_specialtyPediatricsPercentilePrognosiPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioRate ratioPulmonary Disease Chronic ObstructiveElderly populationInternal medicineForced Expiratory VolumeHumansMedicineElderly peopleRespiratory Function TestAgedCOPDmedicine.diagnostic_testbusiness.industryRespiratory Function Tests; Spirometry; Humans; Treatment Outcome; Prognosis; Case-Control Studies; Aged; Middle Aged; Forced Expiratory Volume; Male; Female; Pulmonary Disease Chronic ObstructiveCase-control studyrespiratory systemMiddle AgedPrognosismedicine.diseaseRespiratory Function Testsrespiratory tract diseasesTreatment OutcomeSpirometryCase-Control StudiesFemalebusinessCase-Control StudieHuman
researchProduct

Isolated Pulmonary Embolism Is Associated With a High Risk of Arterial Thrombotic Disease

2020

Background Isolated PE is associated with a higher burden of atherosclerotic disease than other manifestations of VTE. Research Question We hypothesized that the presence of isolated PE may signal a chronically elevated risk of arterial thrombotic disease. Study Design and Methods Data from the VTEval Study, a prospective cohort study enrolling individuals with clinical suspicion and imaging-based diagnosis or exclusion of VTE, were analyzed. Patients with PE received whole-leg ultrasonography to assess presence of DVT. Regularized logistic regression identified features that discriminate between isolated PE and other VTE phenotypes at clinical presentation. Survival analyses were performed…

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryHazard ratioAtrial fibrillationCritical Care and Intensive Care Medicinemedicine.diseaseRate ratioThrombosisPulmonary embolismCoronary artery diseaseInternal medicinemedicineCardiologycardiovascular diseasesMyocardial infarctionCardiology and Cardiovascular MedicineProspective cohort studybusinessChest
researchProduct

COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction

2022

ObjectiveThe initial data of the International Study on Acute Coronary Syndromes - ST Elevation Myocardial Infarction COVID-19 showed in Europe a remarkable reduction in primary percutaneous coronary intervention procedures and higher in-hospital mortality during the initial phase of the pandemic as compared with the prepandemic period. The aim of the current study was to provide the final results of the registry, subsequently extended outside Europe with a larger inclusion period (up to June 2020) and longer follow-up (up to 30 days).MethodsThis is a retrospective multicentre registry in 109 high-volume primary percutaneous coronary intervention (PPCI) centres from Europe, Latin America, S…

RegistrieMaleST Elevation Myocardial Infarction/diagnosisTime FactorsPercutaneousmedicine.medical_treatmentVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Coronary Artery DiseasePractice Patterns030204 cardiovascular system & hematologyRate ratioTime-to-Treatment/trendsCardiologists0302 clinical medicineRetrospective StudieHeart RateRisk FactorsPandemicST segmentRegistriesHospital Mortality030212 general & internal medicineMyocardial infarctionPractice Patterns Physicians'10. No inequalityPercutaneous Coronary Intervention/adverse effectsHospital Mortality/trendsCOVID-19; myocardial infarction; percutaneous coronary interventionIncidenceIncidence (epidemiology)*percutaneous coronary interventionMiddle Aged3. Good healthTreatment Outcomemyocardial infarctionCardiologyFemale*COVID-19Cardiology and Cardiovascular MedicineCardiologists/trendsHumanCOVID-19; myocardial infarction; percutaneous coronary intervention; Aged; Cardiologists; Female; Hospital Mortality; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Practice Patterns Physicians'; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Time-to-Treatment; Treatment Outcome; COVID-19medicine.medical_specialtyTime FactorCoronavirus disease 2019 (COVID-19)CardiologistRisk AssessmentTime-to-Treatment03 medical and health sciencesInternal medicinemedicineHumansAcute Coronary SyndromePandemicsRetrospective StudiesAgedPhysicians'SARS-CoV-2business.industryRisk FactorCOVID-19 myocardial infarction percutaneous coronary interventionpercutaneous coronary interventionPercutaneous coronary interventionCOVID-19*myocardial infarctionmedicine.diseasePractice Patterns Physicians'/trendsST Elevation Myocardial Infarctionbusiness
researchProduct

Validation of the French national health insurance information system as a tool in vaccine safety assessment: Application to febrile convulsions afte…

2013

In the French national health insurance information system (SNIIR-AM), routine records of health claimed reimbursements are linked to hospital admissions for the whole French population. The main focus of this work is the usability of this system for vaccine safety assessment programme. Self-controlled case series analyses were performed using an exhaustive SNIIR-AM extraction of French children aged less than 3 years, to investigate the relationship between MMR immunization and children hospitalizations for febrile convulsions, a well-documented rare adverse event, over 2009-2010. The results suggest a significant increase of febrile convulsions during the 6-11 days period following any MM…

RiskPediatricsmedicine.medical_specialtyNational Health ProgramsMeasles-Mumps-Rubella VaccinePopulationRate ratioSeizures FebrilePneumococcal conjugate vaccine03 medical and health sciences0302 clinical medicine030225 pediatricsProduct Surveillance PostmarketingAdverse Drug Reaction Reporting SystemsHumansMedicine030212 general & internal medicineeducationAdverse effectImmunization ScheduleComputingMilieux_MISCELLANEOUSeducation.field_of_studyGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantICD-103. Good healthHospitalizationVaccinationInfectious DiseasesImmunizationChild PreschoolMolecular Medicine[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFrancebusiness[STAT.ME]Statistics [stat]/Methodology [stat.ME]Measles-Mumps-Rubella Vaccinemedicine.drug
researchProduct

Transportation noise and risk of stroke: a nationwide prospective cohort study covering Denmark

2021

AbstractBackgroundStudies on transportation noise and incident stroke are few and inconclusive. We aimed to investigate associations between road-traffic and railway noise and the risk of incident stroke in the entire Danish population.MethodsWe estimated road-traffic and railway noise (Lden) at the most and least exposed façades for all residential addresses across Denmark (2.8 million) for the period 1990–2017. Based on this, we estimated the 10-year time-weighted mean noise exposure for 3.6 million Danes aged >35 years, of whom 184 523 developed incident stroke during follow-up from 2000 to 2017. Analyses were conducted using Cox proportional-hazards models, with adjustment for va…

Transportation noisemedicine.medical_specialtyEpidemiologybusiness.industryroad-Traffic noiseGeneral Medicine030204 cardiovascular system & hematologyRate ratiomedicine.diseaserailway noiseConfidence interval03 medical and health sciencesNoise0302 clinical medicineEpidemiologymedicineepidemiology030212 general & internal medicineRisk factorProspective cohort studybusinessincident strokeStrokeRailway noiseDemographyInternational Journal of Epidemiology
researchProduct

Reslizumab (RES) in patients (pts) with inadequately controlled asthma and elevated blood eosinophils (EOS): Analysis of two phase 3, placebo-control…

2016

Background: RES reduced exacerbation frequency and improved lung function and asthma control in pts with inadequately controlled asthma and elevated blood EOS in two placebo (PBO)-controlled, phase 3 studies (Castro et al. Lancet Resp Med 2015). Aims/objectives: To determine the efficacy of RES in the subset of pts in these studies meeting the definition of ATS/ERS-defined inadequately controlled asthma. Methods: This was a post-hoc analysis of pooled data from two replicate, 52-week, PBO-controlled studies of RES (3mg/kg IV Q4W) in pts with inadequately controlled asthma and blood EOS ≥400/µL who were using medium-to-high dose inhaled corticosteroids; primary results have been reported. As…

education.field_of_studymedicine.medical_specialtyExacerbationbusiness.industryPopulationRate ratioPlacebomedicine.diseaseElevated bloodrespiratory tract diseases03 medical and health sciences0302 clinical medicine030228 respiratory systemReslizumabQuality of lifeInternal medicineImmunologymedicine030212 general & internal medicineeducationbusinessmedicine.drugAsthma5.1 Airway Pharmacology and Treatment
researchProduct

Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism-Results from the thrombEVAL Study.

2020

Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a telemedicine-based coagulation service (CS). The thrombEVAL study (NCT01809015) is a prospective, multi-center study to investigate OAC treatment (recruitment: January 2011&ndash

medicine.medical_specialtyANTITHROMBOTIC THERAPYPULMONARY-EMBOLISMvenous thromboembolismlcsh:Medicine030204 cardiovascular system & hematologyRate ratioWARFARINArticle03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicineORAL ANTICOAGULATION030212 general & internal medicineAdverse effectcoagulation serviceINR CONTROLNORMALIZED RATIO CONTROLPRACTICAL MANAGEMENTbusiness.industrySTROKE PREVENTIONlcsh:RHazard ratioWarfarinAtrial fibrillationGeneral Medicinemedicine.diseaseConfidence intervalMEDICAL-CAREPulmonary embolismvitamin K antagonistsATRIAL-FIBRILLATIONe-healthbusinessoral anticoagulation therapymedicine.drugJournal of clinical medicine
researchProduct